Literature DB >> 3122349

A randomized trial on the effect of mannitol on postoperative renal function in patients with obstructive jaundice.

J M Gubern1, J J Sancho, J Simó, A Sitges-Serra.   

Abstract

A randomized trial was undertaken to reassess the effectiveness of mannitol in preventing postoperative renal impairment in patients with obstructive jaundice. The study included 31 patients with obstructive jaundice (bilirubin, 3 mg/dl or higher) randomly allocated in two groups to receive (n = 17) or not receive (n = 14) preoperative mannitol. Sixty-five percent of patients had a creatinine clearance below 70 ml/min before surgery. Serum bilirubin and bacteribilia had no relation with preoperative renal function. No relation was found between serum bilirubin value and the percentage fall in postoperative creatinine clearance. Compared with the preoperative values, the postoperative creatinine clearance was significantly impaired in the mannitol group (p = 0.03) and remained almost unaltered in the no-mannitol group. Three patients (9.7%) died of acute renal failure; two were in the mannitol group and one was in the no-mannitol group. Serum fibrin degradation products were not sensitive markers for impending renal failure. There was no significant difference in postoperative serum sodium concentration or in the urinary sodium excretion. Administration of mannitol did not improve the postoperative renal function of jaundiced patients, nor did it prove beneficial in preventing renal failure. Our results suggest that severe disturbances of body-fluid compartments may be the basic mechanism underlying kidney dysfunction in obstructive jaundice and that further water depletion induced by mannitol may indeed prove detrimental.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3122349

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  13 in total

1.  Factors affecting morbidity and mortality in biliary tract surgery.

Authors:  C H Su; F K P'eng; W Y Lui
Journal:  World J Surg       Date:  1992 May-Jun       Impact factor: 3.352

Review 2.  The current standard of care in the periprocedural management of the patient with obstructive jaundice.

Authors:  D L Clarke; Y Pillay; F Anderson; S R Thomson
Journal:  Ann R Coll Surg Engl       Date:  2006-11       Impact factor: 1.891

Review 3.  Acute kidney injury.

Authors:  John A Kellum; Mark L Unruh; Raghavan Murugan
Journal:  BMJ Clin Evid       Date:  2011-03-28

4.  Improved cardiac function in patients with obstructive jaundice after internal biliary drainage: hemodynamic and hormonal assessment.

Authors:  J Padillo; J Puente; M Gómez; F Dios; A Naranjo; J A Vallejo; G Miño; C Pera; A Sitges-Serra
Journal:  Ann Surg       Date:  2001-11       Impact factor: 12.969

Review 5.  Acute renal failure in children: aetiology and management.

Authors:  G Filler
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure.

Authors:  M K Dishart; J A Kellum
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 7.  Acute kidney injury clinical trial design: old problems, new strategies.

Authors:  Zoltán H Endre; John W Pickering
Journal:  Pediatr Nephrol       Date:  2012-05-26       Impact factor: 3.714

Review 8.  Acute renal failure.

Authors:  John A Kellum; Martine Leblanc; Ramesh Venkataraman
Journal:  BMJ Clin Evid       Date:  2008-09-03

9.  Rapid increase in plasma levels of atrial natriuretic peptide after common bile duct ligation in the rabbit.

Authors:  J Valverde; F Martínez-Ródenas; J A Pereira; X Carulla; W Jiménez; J M Gubern; A Sitges-Serra
Journal:  Ann Surg       Date:  1992-11       Impact factor: 12.969

10.  Prevention of postoperative complications in jaundiced rats. Internal biliary drainage versus oral lactulose.

Authors:  J W Greve; J G Maessen; T Tiebosch; W A Buurman; D J Gouma
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.